Sagar Lonial
#122,119
Most Influential Person Now
Researcher
Sagar Lonial's AcademicInfluence.com Rankings
Sagar Lonialmedical Degrees
Medical
#1884
World Rank
#2265
Historical Rank
Pharmacology
#184
World Rank
#223
Historical Rank
Sagar Lonialphilosophy Degrees
Philosophy
#5566
World Rank
#8404
Historical Rank
Logic
#2824
World Rank
#3883
Historical Rank
Download Badge
Medical Philosophy
Sagar Lonial's Degrees
- Doctorate Medicine University of Louisville
- PhD Pharmacology University of Louisville
Why Is Sagar Lonial Influential?
(Suggest an Edit or Addition)Sagar Lonial's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (2014) (2949)
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (2012) (2913)
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. (2005) (1965)
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (2016) (1536)
- Initial genome sequencing and analysis of multiple myeloma (2011) (1385)
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. (2015) (1274)
- Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. (2007) (1231)
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. (2015) (1072)
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. (2011) (862)
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010) (813)
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (2008) (764)
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009) (718)
- Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. (2006) (706)
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. (2014) (703)
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial (2016) (685)
- Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth (2009) (681)
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. (2012) (608)
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. (2021) (586)
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. (2016) (582)
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. (2015) (532)
- Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. (2007) (515)
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. (2019) (388)
- Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. (2017) (382)
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. (2019) (346)
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. (2015) (340)
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. (2014) (339)
- Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. (2012) (336)
- Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. (2005) (326)
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. (2009) (322)
- Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. (2017) (320)
- International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. (2014) (318)
- Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies (2013) (312)
- Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline (2009) (300)
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. (2011) (295)
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. (2013) (289)
- Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. (2012) (285)
- Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. (2011) (283)
- Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. (2018) (279)
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis (2018) (266)
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. (2012) (262)
- Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. (2009) (259)
- Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. (2007) (257)
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. (2014) (239)
- Management of treatment-emergent peripheral neuropathy in multiple myeloma (2012) (229)
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. (2014) (223)
- Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. (2013) (221)
- Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. (2009) (220)
- Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. (2014) (220)
- Treatment Options for Relapsed and Refractory Multiple Myeloma (2011) (213)
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. (2019) (213)
- New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) (2014) (211)
- International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (2009) (202)
- Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. (2010) (200)
- Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. (2014) (195)
- 6-phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumor growth by inhibiting LKB1-AMPK signaling (2014) (189)
- Tyrosine Phosphorylation of Lactate Dehydrogenase A Is Important for NADH/NAD+ Redox Homeostasis in Cancer Cells (2011) (187)
- A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease (2013) (181)
- Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study (2008) (180)
- A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. (2014) (180)
- Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (2017) (170)
- The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. (2007) (169)
- Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. (2008) (159)
- Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients (2014) (154)
- Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. (2009) (153)
- Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma (2015) (150)
- FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. (2006) (149)
- International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation (2009) (143)
- In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
- Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. (2017) (138)
- American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip (2015) (134)
- Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. (2019) (133)
- Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. (2015) (132)
- Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers (2011) (131)
- Association of response endpoints with survival outcomes in multiple myeloma (2013) (129)
- Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. (2019) (128)
- An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. (2012) (125)
- Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. (2010) (124)
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. (2020) (123)
- Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. (2011) (123)
- Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation (2001) (123)
- Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients (2008) (122)
- Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. (2003) (120)
- Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. (2011) (115)
- Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT‐2 follow‐up and post‐hoc analyses on progression‐free survival and tumour growth (2017) (115)
- Panobinostat for the treatment of multiple myeloma (2012) (115)
- Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma (2007) (114)
- Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma (2012) (114)
- Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. (2016) (113)
- Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial (2018) (113)
- Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. (2016) (113)
- High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma (2017) (112)
- Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. (2015) (112)
- Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study (2011) (109)
- Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. (2017) (109)
- Monoclonal gammopathy of undetermined significance: a consensus statement (2010) (107)
- A practical update on the use of bortezomib in the management of multiple myeloma. (2006) (104)
- Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma (2010) (103)
- Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax (2015) (102)
- Salvage second hematopoietic cell transplantation in myeloma. (2013) (101)
- High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action (2018) (100)
- Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. (2013) (100)
- Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. (2014) (99)
- Daratumumab Plus Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. (2019) (98)
- Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. (2014) (95)
- Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. (2020) (95)
- The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway (2007) (94)
- Effectiveness and cost analysis of “just‐in‐time” salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics (2011) (94)
- Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. (2020) (93)
- Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma (2008) (93)
- Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. (2014) (93)
- Proteasome Inhibitor PS-341 (Bortezomib) Induces Calpain-dependent IκBα Degradation* (2010) (92)
- Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (2019) (91)
- A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study (2010) (91)
- Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. (2020) (87)
- Multiple myeloma immunoglobulin lambda translocations portend poor prognosis (2019) (86)
- An expanded universe of cancer targets (2021) (86)
- How I treat high-risk myeloma. (2015) (85)
- Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. (2011) (80)
- Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation (2013) (80)
- Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice (2016) (79)
- Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. (2019) (78)
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
- Hematopoietic Cell Transplantation for Primary Plasma Cell Leukemia: Results from the Center for International Blood and Marrow Transplant Research (2011) (77)
- Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study (2008) (77)
- Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives (2015) (76)
- Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study (2013) (76)
- Monoclonal antibodies in the treatment of multiple myeloma (2011) (75)
- PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. (2007) (75)
- Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. (2017) (75)
- Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. (2002) (75)
- Older patients with myeloma derive similar benefit from autologous transplantation. (2014) (74)
- Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. (2012) (74)
- Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax (2015) (73)
- Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. (2001) (73)
- MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. (2018) (72)
- Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. (2011) (72)
- Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease. (1999) (71)
- Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma (2015) (71)
- Treatment options for relapsed and refractory multiple myeloma. (2015) (68)
- Daratumumab in multiple myeloma (2019) (66)
- MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. (2011) (65)
- Review of peripheral neuropathy in plasma cell disorders (2008) (64)
- Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients (2019) (63)
- Current strategies for treatment of relapsed/refractory multiple myeloma (2014) (62)
- Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study (2020) (62)
- The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. (2005) (61)
- Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment (2016) (61)
- Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial. (2005) (61)
- BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity (2012) (61)
- Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. (2016) (61)
- Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. (2010) (61)
- Clinical uses of GM-CSF, a critical appraisal and update (2008) (59)
- MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma (2016) (59)
- Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study (2020) (58)
- 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells. (2007) (58)
- Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. (2017) (57)
- Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. (2019) (56)
- Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma (2017) (56)
- Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation (2009) (55)
- Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease. (2009) (55)
- Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. (2020) (55)
- The Tao of myeloma. (2014) (55)
- Current developments in immunotherapy in the treatment of multiple myeloma (2018) (55)
- Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study (2021) (53)
- Academic, Foundation, and Industry Collaboration in Finding New Therapies (2017) (53)
- Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma (2020) (52)
- Safety of proteasome inhibitors for treatment of multiple myeloma (2016) (52)
- Relapsed multiple myeloma. (2010) (51)
- Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to anti-malarial agent dihydroartemisinin (2016) (50)
- Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM). (2004) (50)
- SECOND TRANSPLANTS FOR MULTIPLE MYELOMA RELAPSING AFTER A PRIOR AUTOTRANSPLANT – REDUCED INTENSITY ALLOGENEIC VERSUS AUTOLOGOUS TRANSPLANTATION (2013) (49)
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. (2022) (49)
- Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib (2014) (48)
- Non-secretory myeloma: a clinician's guide. (2013) (48)
- Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial (2011) (47)
- Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM) (2010) (47)
- Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma (2016) (47)
- Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma (2006) (47)
- Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study. (2008) (47)
- Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma (2017) (46)
- Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells (2013) (46)
- Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma (2017) (46)
- A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM) (2011) (44)
- Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma (2015) (44)
- BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (2011) (44)
- A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results (2012) (44)
- A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma (2017) (43)
- The NEDD8-Activating Enzyme Inhibitor, MLN4924, Cooperates with TRAIL to Augment Apoptosis through Facilitating c-FLIP Degradation in Head and Neck Cancer Cells (2011) (43)
- Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis (2011) (43)
- Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia (2012) (43)
- Neosartorya fischeri: an invasive fungal pathogen in an allogeneic bone marrow transplant patient (1997) (42)
- A Phase II Study of Oral Panobinostat (LBH589) in Adult Patients with Advanced Refractory Multiple Myeloma (2008) (41)
- Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial (2020) (41)
- When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response (2015) (41)
- Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials (2020) (41)
- A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma (2017) (41)
- A Multicenter Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib (BZ): Encouraging Activity and Manageable Toxicity in Heavily Pre-Treated Patients with Relapsed Refractory Multiple Myeloma (MM). (2006) (40)
- Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. (2013) (40)
- YAP1 Expression in Small Cell Lung Cancer Defines a Distinct Subtype with T-cell Inflamed Phenotype. (2020) (40)
- A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. (2004) (39)
- Multi-Center Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Promising Activity as Combination Therapy with Manageable Toxicity. (2007) (39)
- Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. (2009) (39)
- Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance (2019) (39)
- Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients (2011) (39)
- Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression (2012) (38)
- Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study. (2017) (38)
- Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors (2008) (37)
- Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2014) (37)
- New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma (2016) (37)
- Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients (2013) (36)
- Bortezomib‐containing induction regimens in transplant‐eligible myeloma patients (2013) (36)
- Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail. (2005) (35)
- Integration of Novel Agents into the Care of Patients with Multiple Myeloma (2016) (34)
- Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation (2016) (34)
- Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma (2009) (34)
- Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study. (2007) (34)
- Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia? (2016) (34)
- γ-6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A. (2019) (34)
- High‐risk Multiple Myeloma: Definition and Management (2017) (34)
- Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. (2003) (34)
- Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma (2019) (34)
- MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM) (2013) (33)
- New cancers after autotransplantations for multiple myeloma. (2015) (33)
- Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 (2016) (33)
- First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (2019) (33)
- Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients (2016) (32)
- Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. (2004) (32)
- Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib (2008) (32)
- ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM) (2013) (32)
- Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up (2015) (32)
- Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma (2010) (32)
- Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study (2019) (31)
- The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study (2012) (31)
- Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study. (2007) (31)
- Racial differences in the incidence and outcomes for patients with hematological malignancies. (2007) (31)
- Characteristics and outcomes of diffuse large B‐cell lymphoma presenting in leukaemic phase (2012) (31)
- Editorial :Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). DOI: 10.1080/15548627.2015.1100356;WOS:000373595400001; 2-s2.0-85013763791&;PMID: 26799652 (2016) (31)
- Investigational Agent MLN9708, An Oral Proteasome Inhibitor, in Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (MM): Results From the Expansion Cohorts of a Phase 1 Dose-Escalation Study (2011) (31)
- Epidermal Growth Factor Stimulates RSK2 Activation through Activation of the MEK/ERK Pathway and Src-dependent Tyrosine Phosphorylation of RSK2 at Tyr-529* (2008) (30)
- Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation. (2007) (30)
- Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR (2021) (30)
- Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up (2010) (30)
- Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study (2020) (30)
- Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents (2018) (30)
- Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes (2011) (29)
- Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma (2017) (29)
- Acquired amegakaryocytic thrombocytopenia treated with allogeneic BMT: a case report and review of the literature (1999) (29)
- Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study (2010) (29)
- Maintenance therapy in multiple myeloma (2007) (29)
- Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. (2014) (28)
- Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial. (2020) (28)
- Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results (2014) (28)
- Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. (2020) (28)
- Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). (2010) (28)
- Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study (2017) (28)
- Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. (2010) (27)
- Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1, (2011) (27)
- Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma (2017) (26)
- A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly High Rates of Baseline Peripheral Neuropathy. (2005) (26)
- Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma (2017) (26)
- Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs). (2020) (26)
- Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study. (2012) (26)
- Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma (2013) (26)
- DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN–WEE1 Signaling (2020) (25)
- First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2020) (25)
- Interim Analysis Of The Mmrf Commpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles (2013) (25)
- Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma. (2014) (25)
- Ixazomib for the treatment of multiple myeloma (2018) (25)
- Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. (2018) (24)
- Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression (2021) (24)
- Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study (2012) (24)
- Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma (2018) (24)
- Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects. (2009) (24)
- Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft‐versus‐host disease (2010) (24)
- Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma (2012) (23)
- Phase I Study of the Combination of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multiple Myeloma Research Consortium (MMRC) Clinical Trial (2014) (23)
- Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study. (2004) (23)
- Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma (2017) (23)
- Reconstructing immunity after allogeneic transplantation (2004) (23)
- HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers (2017) (23)
- Deacetylase inhibitors: an advance in myeloma therapy? (2017) (23)
- Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells (2007) (23)
- Phase II Study of the Pan-Deacetylase Inhibitor Panobinostat in Combination with Bortezomib and Dexamethasone in Relapsed and Bortezomib-Refractory Multiple Myeloma (PANORAMA 2) (2011) (22)
- Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety. (2013) (22)
- Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis (2015) (22)
- ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (2015) (22)
- Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory Myeloma (ACE-MM-102 Study) (2015) (22)
- Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study (2020) (22)
- Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes (2016) (22)
- Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study (2008) (21)
- Presentation and risk stratification--improving prognosis for patients with multiple myeloma. (2010) (21)
- MM-008: A Phase 1 Trial Evaluating Pharmacokinetics and Tolerability Of Pomalidomide + Low-Dose Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment (2013) (21)
- First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (2020) (21)
- Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity (2005) (21)
- ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006). (2012) (20)
- Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma (2017) (20)
- Interim Analysis of the Mmrf Commpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression (2014) (20)
- Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study. (2009) (20)
- A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci (2016) (20)
- A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183. (2018) (20)
- Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results. (2021) (20)
- The era of combination therapy in myeloma. (2012) (20)
- A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low‐grade B‐cell lymphomas (2012) (20)
- Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. (2019) (20)
- Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy. (2018) (19)
- Subcutaneous Versus Intravenous Bortezomib (2013) (19)
- Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM) (2021) (19)
- Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220) (2019) (19)
- Induction therapy for newly diagnosed multiple myeloma. (2013) (19)
- A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185. (2018) (19)
- Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study (2010) (19)
- Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial (2009) (19)
- Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM). (2005) (19)
- Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma (2008) (19)
- Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma (2017) (19)
- Maintenance therapy in lymphoma. (2007) (18)
- Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor (2018) (18)
- Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma (2005) (18)
- Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM) (2014) (18)
- Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM). (2012) (18)
- The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. (2007) (18)
- Hematologic Profiles in the Phase 3 APEX Trial. (2005) (18)
- How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. (2016) (18)
- Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients. (2021) (18)
- Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature. (2011) (18)
- Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001 (2017) (18)
- Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results. (2009) (18)
- Phase I/II Report from a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib. (2007) (17)
- Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. (2022) (17)
- HLA polymorphism and risk of multiple myeloma (2016) (17)
- Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM). (2006) (17)
- BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth (2016) (17)
- Neutropenia Is a Predictable and Early Event in Affected Patients with Relapsed/Refractory Multiple Myeloma Treated with Lenalidomide in Combination with Dexamethasone. (2009) (17)
- Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma (2019) (17)
- Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study (2020) (17)
- Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: res (2013) (17)
- Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study (2010) (17)
- Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients with Symptomatic Multiple Myeloma. (2007) (17)
- Patient‐reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double‐blind, placebo‐controlled PANORAMA‐1 trial (2018) (17)
- Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM). (2009) (17)
- Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) (2010) (16)
- SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents. (2019) (16)
- Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. (2019) (16)
- Integrated Analysis of Whole-Genome Paired-End and Mate-Pair Sequencing Data for Identifying Genomic Structural Variations in Multiple Myeloma (2014) (16)
- A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses. (2002) (16)
- Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius) (2015) (16)
- Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM) (2013) (16)
- Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. (2013) (16)
- Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. (2019) (16)
- Eliminating the complete response penalty from myeloma response assessment. (2008) (16)
- A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma (2018) (16)
- Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010. (2011) (15)
- Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study (2017) (15)
- ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study (2011) (15)
- Tanespimycin + Bortezomib Demonstrates Safety, Activity, and Effective Target Inhibition in Relapsed/Refractory Myeloma Patients: Updated Results of a Phase 1/2 Study. (2009) (15)
- Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH (2020) (15)
- Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM) (2010) (15)
- Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma (2012) (15)
- Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma (2021) (15)
- Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors (2014) (15)
- A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM). (2006) (14)
- Safety and Efficacy of Bortezomib in Multiple Myeloma Patients with Renal Failure Requiring Dialysis. (2005) (14)
- Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma (2013) (14)
- A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. (2020) (14)
- Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study (2017) (14)
- Targeting 14-3-3 Sensitizes Native and Mutant BCR-ABL to Inhibition with U0126, Rapamycin and Bcl-2 Inhibitor GX15-070. (2007) (14)
- Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study (2018) (14)
- Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis (2012) (14)
- Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration (2021) (14)
- Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. (2019) (14)
- PANORAMA 2: Panobinostat Combined with Bortezomib and Dexamethasone in Patients with Relapsed and Bortezomib-Refractory Multiple Myeloma (2012) (14)
- Is there still a role for stem cell transplantation in multiple myeloma? (2019) (14)
- Regulation of alloimmune responses by dendritic cell subsets. (2008) (14)
- Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial (2017) (14)
- Larger numbers of CD 4 bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation (2001) (14)
- E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. (2019) (14)
- Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results. (2009) (14)
- 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors (2018) (13)
- A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2011) (13)
- Risky business in myeloma. (2009) (13)
- The Role of Early Intervention in High-Risk Smoldering Myeloma. (2020) (13)
- Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study. (2010) (13)
- Novel drug combinations for the management of relapsed/refractory multiple myeloma. (2014) (13)
- Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM) (2008) (13)
- Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. (2008) (13)
- A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005) (2015) (13)
- Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib (2013) (13)
- PHARMACODYNAMIC RELATIONSHIP BETWEEN NATURAL KILLER CELLS AND DARATUMUMAB EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (2016) (13)
- Novel Combination Treatments in Multiple Myeloma. (2016) (13)
- Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma (2022) (13)
- MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma (2012) (13)
- CD86 regulates myeloma cell survival. (2017) (13)
- PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis. (2011) (13)
- Bortezomib in Combination with Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin (V-DCEP) for the Treatment of Multiple Myeloma (2014) (13)
- Multiple myeloma: the role of transplant and novel treatment strategies. (2004) (12)
- Elotuzumab: serum protein electrophoresis and immunofixation interference with clinical assessment of M-protein response in relapsed/refractory multiple myeloma (RRMM) (2015) (12)
- Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001. (2018) (12)
- The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs), (2011) (12)
- A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non‐Hodgkin's lymphoma (2015) (12)
- Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma (2013) (12)
- An open-label, single arm, phase IIa study of bortezomib, lenalidomide, dexamethasone, and elotuzumab in newly diagnosed multiple myeloma. (2017) (12)
- Identification of Alpha 1-Acid Glycoprotein (AAG) As a Potential Patient Selection Biomarker for Improved Clinical Activity of the Novel KSP Inhibitor ARRY-520 in Relapsed and Refractory Multiple Myeloma (MM) (2012) (12)
- Effect of acute and chronic graft-versus-host disease on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma (2011) (12)
- Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation. (2010) (12)
- Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and Sirius (2017) (11)
- The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. (2018) (11)
- Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma. (2013) (11)
- Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Two Doses of Bortezomib (Btz) in Patients with Relapsed Multiple Myeloma (MM). (2006) (11)
- Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer. (2010) (11)
- Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. (2018) (11)
- Signal Transduction and Myeloma: New Targets, New Hope (2003) (11)
- Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations and Outcomes. (2020) (11)
- PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma. (2012) (11)
- Myeloma Is Not a Single Disease. (2016) (11)
- Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomib, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM). (2012) (11)
- High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study. (2009) (11)
- Rapid hematopoietic engraftment following fractionated TBI conditioning and transplantation with CD34+ enriched hematopoietic progenitor cells from partially mismatched related donors (2002) (11)
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies (2019) (11)
- Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström Macroglobulinemia (2015) (11)
- Initial Results of a Phase 1/2a, Dose Escalation Study of PVX-410 Multi-Peptide Cancer Vaccine in Patients with Smoldering Multiple Myeloma (SMM) (2014) (11)
- Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma (2016) (11)
- Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study (2016) (11)
- Smoldering Myeloma and the Art of War. (2020) (10)
- Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study (2017) (10)
- Results of a clinical phase I dose-escalation study of cytarabinein combination with fixed-dose vinorelbine, paclitaxel, etoposideand cisplatin for the treatment of relapsed/refractory lymphoma (2006) (10)
- Thalidomide As Maintenance Therapy in Multiple Myeloma (MM) Improves Progression Free Survival (PFS) and Overall Survival (OS): A Meta-Analysis (2011) (10)
- Perspectives on the Risk-Stratified Treatment of Multiple Myeloma (2022) (10)
- Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. (2020) (10)
- Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (2015) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation (2016) (10)
- Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents (2020) (10)
- High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action (2016) (10)
- A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: Initial results. (2016) (10)
- Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. (2022) (10)
- A Phase I/II Trial of Ixazomib (Ix), Pomalidomide (POM), and Dexamethasone (DEX), in Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients: Responses in Double/Triple Refractory Myeloma and Poor Risk Cytogenetics (2016) (10)
- Gene integrated set profile analysis: a context-based approach for inferring biological endpoints (2016) (10)
- Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. (2021) (9)
- New Targets and New Agents in High-Risk Multiple Myeloma. (2016) (9)
- Treatment of relapsed and refractory myeloma (2009) (9)
- Antibody treatment in multiple myeloma. (2021) (9)
- Cardiac and Pulmonary Safety Profile of Single-Agent Carfilzomib From Four Phase 2 Studies in Patients with Relapsed and/or Refractory Multiple Myeloma (2012) (9)
- Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts) (2007) (9)
- Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). (2017) (9)
- Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. (2021) (9)
- Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). (2018) (9)
- Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial (2021) (9)
- Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent (2017) (9)
- Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models (2019) (9)
- Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. (2018) (9)
- CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman’s Disease: Preliminary Results of a Phase I Study. (2008) (9)
- PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. (2011) (9)
- New Targets and New Agents in High-Risk Multiple Myeloma. (2016) (9)
- A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma. (2008) (9)
- Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting (2021) (9)
- The Importance of Complete Response in Outcomes in Myeloma (2009) (8)
- Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data (2013) (8)
- Analysis of Varicella Zoster Virus Reactivation among Bortezomib-Treated Patients in the APEX Study. (2006) (8)
- Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. (2009) (8)
- The future of drug development and therapy in myeloma. (2013) (8)
- Lack of health maintenance examinations and risk in myeloma patients (2016) (8)
- Panobinostat for the treatment of multiple myeloma (2015) (8)
- Proteasome Inhibition: Novel Therapy for Multiple Myeloma (2006) (8)
- Precision medicine in multiple myeloma: are we there yet? (2019) (8)
- Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma. (2011) (8)
- Bayesian Network Models of Multiple Myeloma: Drivers of High Risk and Durable Response (2016) (8)
- Natural history of multiple myeloma patients refractory to venetoclax: A single center experience (2020) (8)
- Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4. (2016) (8)
- Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (2014) (8)
- Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed/Refractory Multiple Myeloma (2020) (8)
- Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma (2020) (8)
- 150: A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration (2007) (8)
- Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. (2022) (8)
- Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. (2014) (8)
- DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment. (2020) (8)
- P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY (2022) (8)
- YAP1 positive small-cell lung cancer subtype is associated with the T-cell inflamed gene expression profile and confers good prognosis and long term survival. (2020) (8)
- Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma (2021) (8)
- Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma (2021) (8)
- Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study (2011) (8)
- Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial. (2013) (7)
- Plerixafor in combination with granulocyte–colony‐stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial (2015) (7)
- Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. (2021) (7)
- Sequential or combination therapy for multiple myeloma (2012) (7)
- Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma (2015) (7)
- Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma. (2009) (7)
- Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas (2019) (7)
- Designing risk-adapted therapy for multiple myeloma: the Mayo perspective. (2007) (7)
- Cereblon Splicing of Exon 10 Mediates IMiDs Resistance in Multiple Myeloma: Clinical Validation in the CoMMpass Trial (2016) (7)
- A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma (2021) (7)
- Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. (2011) (7)
- Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM). (2019) (7)
- Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis. (2013) (7)
- Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. (2022) (7)
- DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics. (2020) (7)
- CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma. (2017) (7)
- A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma. (2007) (7)
- Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) (2020) (7)
- Optimizing the management of treatment-related peripheral neuropathy in patients with multiple myeloma. (2006) (7)
- Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study (2014) (7)
- The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM) (2011) (7)
- "A fortuitous combination of circumstances". (2013) (7)
- High Dose Chemotherapy Without Hematopoietic Cell Support for the Treatment of Refractory Lymphoma (2000) (7)
- High-risk multiple myeloma: does it still exist? (2011) (6)
- Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses (2020) (6)
- A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2019) (6)
- Combination of Bortezomib with Tipifarnib (R115777) Induces Synergistic Myeloma Cell Apoptosis Via Down-Regulation of HDAC6 and Inhibition of Aggresome Formation. (2007) (6)
- Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study (2021) (6)
- A Vascular Targeted Pan PI-3 Kinase Inhibitor, SF1126 with Activity Against Multiple Myeloma In Vivo. (2006) (6)
- PANORAMA 2: A phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM). (2010) (6)
- Is Subcutaneous Bortezomib Ready for Prime Time? (2011) (6)
- A329 Panobinostat and Lenalidomide Combination Phase I Trial in Myeloma (2009) (6)
- ELOQUENT-2 update: Phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM)--Identifying responders by subset analysis. (2016) (6)
- Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38 (2016) (6)
- Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial (2019) (6)
- Novel treatment approaches for patients with multiple myeloma. (2006) (6)
- Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy (2018) (6)
- 997PDSplit dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM) (2017) (6)
- Multiple myeloma: novel approaches for relapsed disease. (2007) (6)
- Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1. (2015) (6)
- Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy (6)
- A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC). (2019) (6)
- Multiple Myeloma (MM) In Older (>70 year) Patients - Similar Benefit From Autologous Hematopoietic Cell Transplantation (AHCT) Compared With Younger Patients (2013) (6)
- Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma. (2010) (6)
- Colesevelam Hydrochloride for the Treatment of Lenalidomide Induced Diarrhea (2014) (6)
- Allogeneic Stem Cell Transplantation (SCT) for Multiple Myeloma (MM) - What Has Changed? : A CIBMTR Analysis From 1989 – 2005. (2009) (5)
- Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1). (2012) (5)
- A364 A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma (2009) (5)
- Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group (2012) (5)
- MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma. (2014) (5)
- Correction to: Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. (2015) (5)
- DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) Effects on Patient-Reported Outcome (PRO) Measures in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2020) (5)
- A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease. (2008) (5)
- Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD). (2013) (5)
- MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). (2013) (5)
- Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial. (2020) (5)
- Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status (2008) (5)
- A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. (2007) (5)
- Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM) (2019) (5)
- Retrospective analysis of the long term safety of lenalidomide (Len)±dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM) (2011) (5)
- Enhanced Levels of Apoptosis by Combination of Farnesyl Transferase Inhibition (Tipifarnib) and Proteasome Inhibition (Bortezomib) in Myeloma Cell Lines and Primary Myeloma Cells and Its Mechanistic Effects on Akt and Caspase Pathways. (2005) (5)
- Improving Induction Therapy in Multiple Myeloma (2010) (5)
- Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor (2021) (5)
- Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma (2019) (5)
- Multiple Myeloma - a New Era of Treatment Strategies (2012) (5)
- A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma (2010) (5)
- Relapsed and refractory multiple myeloma: new therapeutic strategies. (2014) (5)
- Changes in the pattern of TCR Vβ repertoire expression after bone marrow transplant is linked to the HLA haplotype in humans (2001) (5)
- Impact of Body Mass Index (BMI) On Overall Survival in Myeloma (2012) (5)
- Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma (2020) (5)
- Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience. (2009) (5)
- The myeloma-developing regimens using genomics (MyDRUG) master protocol. (2019) (5)
- Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1. (2012) (5)
- Characterization of Cyclic Hematologic Changes Observed in Patients with Cutaneous T-Cell Lymphoma (CTCL) Receiving Romidepsin, a Novel Histone Deacetylase (HDAC) Inhibitor. (2009) (5)
- Immunomodulation: the role of hematopoietic cytokines. (2004) (4)
- Maturation of Human Long-lived Plasma Cells Results in Resistance to Apoptosis by Transcriptional and Epigenetic Regulation (2021) (4)
- FGFR3 Mutations Are an Adverse Prognostic Factor in Patients with t(4;14)(p16;q32) Multiple Myeloma: An Mmrf Commpass Analysis (2017) (4)
- Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma (2020) (4)
- A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma. (2016) (4)
- MM-347: Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for Newly Diagnosed Multiple Myeloma (NDMM) Patients Not Eligible for Autologous Stem Cell Transplant: The Double-Blind, Placebo-Controlled, Phase 3 TOURMALINE-MM2 Trial (2020) (4)
- Safety and survival outcomes for bloodless transplantation in patients with myeloma (2018) (4)
- Emerging treatments in Castleman disease – a critical appraisal of siltuximab (2016) (4)
- Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. (2020) (4)
- A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors (2020) (4)
- A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma (2013) (4)
- Research participants’ views of nontherapeutic biopsies (2008) (4)
- The Multiple Myeloma Research Foundation (MMRF) CoMMpassSM Study: A Longitudinal Study in Newly-Diagnosed Multiple Myeloma Patients to Assess Genomic Profiles, Immunophenotypes and Clinical Outcomes (2012) (4)
- Correlation Between Somatic Mutation Burden, Neoantigen Load and Progression Free Survival in Multiple Myeloma: Analysis of MMRF CoMMpass Study (2016) (4)
- Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites (2018) (4)
- Interim Analysis of the MMRF CoMMpass Study: Comprehensive Characterization of Multiple Myeloma Patients at Diagnosis Reveals Distinct Molecular Subtypes and Clinical Outcomes (2015) (4)
- Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study (2021) (4)
- Antitumor effects of combined bortezomib and tipifarnib in head and neck squamous cell carcinoma (HNSCC) cells. (2006) (4)
- Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series. (2014) (4)
- A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies. (2012) (4)
- Systematic discovery of mutation-directed neo-protein-protein interactions in cancer (2021) (4)
- Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma (2020) (4)
- Is Maintenance Therapy for Everyone? (2016) (4)
- Smoldering multiple myeloma current treatment algorithms (2022) (4)
- Novel combination approaches for myeloma. (2015) (4)
- Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program (2010) (4)
- Second Malignancies After Autologous Hematopoietic Cell Transplantation (AHCT) for Multiple Myeloma (MM): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis (2012) (4)
- Phase I trial of chir-258 in multiple myeloma. (2006) (4)
- Comprehensive Identification of Fusion Transcripts in Multiple Myeloma: An Mmrf Commpass Analysis (2017) (4)
- Second Transplants in Relapsed Multiple Myeloma (MM): Autologous (AHCT) Versus Non-Myeloablative/Reduced Intensity (NST/RIC) Allogeneic Transplantation (AlloHCT) (2011) (4)
- ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004). (2012) (4)
- The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685) (2017) (4)
- SF1126, a Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequence Specific Synergy When Combined with Bortezomib in Multiple Myeloma Cells (2008) (4)
- Selinexor for the treatment of patients with previously treated multiple myeloma (2021) (4)
- Response Duration with Initial Therapy Is a Major Predictor of Overall Survival in Multiple Myeloma: Analysis from Multiple Phase III ECOG Clinical Trials (2008) (4)
- Hematopoietic Cell Transplant Co-Morbidity Index (HCTCI) and Multiple Myeloma (MM) Survival After Autologous Hematopoietic Cell Transplantation (AHCT) (2012) (4)
- Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ). (2009) (4)
- Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial (2022) (4)
- Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma. (2009) (4)
- Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004 (2005) (4)
- A129 Phase Ib Study of Elotuzumab (HuLuc63) inCombination with Lenalidomide in Relapsed Multiple Myeloma (2009) (4)
- Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma (2018) (4)
- Supportive therapies in multiple myeloma. (2009) (4)
- Thromboembolic Events (TEE) with Lenalidomide-Based Therapies for Multiple Myeloma (MM): Emory Experience. (2009) (4)
- Vorinostat, Bortezomib, Cyclophosphomide, Thalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients (2014) (3)
- Alkaline Phosphatase (ALP) Variation During Carfilzomib Treatment Is Associated to Best Response in Multiple Myeloma. (2009) (3)
- Pre-Transplant Salvage Therapy Prior to Autologous Transplant (AHCT) in Patients Not Responding to Initial Induction for Multiple Myeloma (MM) (2012) (3)
- Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. (2020) (3)
- OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa (2021) (3)
- Efficacy and safety of triplet versus doublet salvage therapies among relapsed myeloma patients: Meta-analysis of phase 3 randomized controlled trials. (2016) (3)
- Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin? (2021) (3)
- Impaired SARS-CoV-2 variant neutralization and CD8+ T cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections. (2022) (3)
- Second Autologous Transplants for Multiple Myeloma (MM) Relapse After a Prior Autologous Transplant (AHCT) – a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR) (2011) (3)
- Four phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma in the newly-diagnosed, relapsed/refractory, and maintenance settings: TOURMALINE-MM1, -MM2, -MM3, and -MM4 (2015) (3)
- Lenalidomide, bortezomib, pegylated liposomal doxorubicin hydrochloride, and dexamethasone in newly diagnosed multiple myeloma: Initial results of phase I/II MMRC trial. (2009) (3)
- Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). (2009) (3)
- Lenalidomide (LEN) Therapy In Combination with Dexamethasone (DEX) Is Associated with a Low Incidence of Viral Infections (2010) (3)
- Daratumumab: monoclonal antibody therapy to treat multiple myeloma. (2016) (3)
- A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. (2012) (3)
- Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001 (2020) (3)
- Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma (2012) (3)
- Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study (2010) (3)
- Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations (2020) (3)
- Breakthroughs in the Management of Multiple Myeloma (2012) (3)
- Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study (2019) (3)
- Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias (2015) (3)
- Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM). (2010) (3)
- Benefits of autologous stem cell transplant for elderly myeloma patients in the last quarter of life. (2021) (3)
- Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma. (2012) (3)
- Results of an Early Access Treatment Protocol (EAP) of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma (2016) (3)
- Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients (2015) (3)
- Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients (2013) (3)
- Efficacy Of ABT-199 In Multiple Myeloma (2013) (3)
- Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease, (2011) (3)
- The current unmet medical needs in the treatment and management of multiple myeloma (MM) (2015) (3)
- Safety Profile of Oral Ixazomib: Experience from 761 Patients (Pts) Across 14 Phase 1 or Phase 1/2 Clinical Studies (2015) (3)
- Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study. (2011) (3)
- Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib (2010) (3)
- Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma (2018) (3)
- RVD is a Superior Induction Regimen Compared to VCD Among Transplant-Eligible Myeloma Patients (2017) (3)
- Abstract 839: Whole genome DNA methylation analysis of multiple myeloma identifies pervasive hypomethylation and biomarkers of survival (2019) (3)
- S1603 FIRST CLINICAL (PHASE 1B/2A) STUDY OF IBERDOMIDE (CC-220; IBER), A CELMOD, IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (2019) (3)
- Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma (2013) (3)
- Management of toxicities associated with bortezomib. (2006) (3)
- Neurotoxic and peripheral neuropathic effects in preclinical and clinical studies of carfilzomib (CFZ), a novel proteasome inhibitor (PI). (2010) (3)
- Combination of Farnesyl Transferase Inhibitor (Tipifarnib) with Perifosine Induces Apoptosis through phos-PDK1 in Human Lymphoma and Leukemia Cell Lines. (2005) (3)
- Patulin, a Mycotoxin, Has Potent Cytotoxic Activity on Actue Lymphoblastic Leukemia and Induce Apoptosis through Intrinsic and Extrinsic Pathways. (2007) (3)
- Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry (2012) (3)
- Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. (2015) (3)
- Combination of Akt/PKB Inhibition (Perifosine) and Farnesyl Transferase Inhibition (Tipifarnib) Results in Increased Cell Death in Myeloma Cells Lines. (2005) (3)
- Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients. (2009) (3)
- Durable Responses with Bortezomib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (MCL): Updated Time-to-Event Analyses of the Multicenter PINNACLE Study. (2007) (3)
- Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study (2019) (3)
- Bortezomib-associated transient and cyclical thrombocytopenia: evidence for lack of marrow cytotoxicity (2005) (3)
- Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitor (PI) and Immunomodulatory Drug (IMiD) Treatment (2015) (3)
- ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with assessment for t(11;14) status. (2019) (3)
- Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis (2011) (3)
- Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study (2019) (3)
- Multiple myeloma immunoglobulin λ translocations portend poor prognosis (2018) (2)
- ASTCT Clinical Practice recommendations for transplant and cellular therapies in multiple myeloma. (2022) (2)
- The proteasome inhibitor PS-341 (Bortezomib) upregulates death receptor 5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite increase of c-FLIP and survivin in human lung cancer cells. (2007) (2)
- Impact of Treatment Duration and Dosing on Efficacy and Safety in a Phase 3 Study of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma (2015) (2)
- Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM) (2019) (2)
- A Randomized Trial To Evaluate the Impact of Cytokines (G-CSF or GM + G-CSF) on Dendritic Cell and T-Cell Content and Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant. (2005) (2)
- A randomized clinical trial comparing granulocyte–colony‐stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation (2011) (2)
- The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics. (2010) (2)
- Recovery and rebound of platelet counts in mice after thrombocytopenia induced by combination bortezomib + romidepsin. (2012) (2)
- A Novel Pan-PI3K/Akt Inhibitor, SF1126, Inhibits In Vitro Growth of Multiple Myeloma Cells. (2007) (2)
- B-Cell Markers Predict Response to Venetoclax in Multiple Myeloma (2016) (2)
- Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial (2011) (2)
- Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival (2022) (2)
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications. (2010) (2)
- Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2020) (2)
- Epidermal Growth Factor Stimulates RSK 2 Activation through Activation of the MEK / ERK Pathway and Src-dependent Tyrosine Phosphorylation of RSK 2 at Tyr-529 (2)
- Addressing unmet medical needs in maintenance treatment for newly diagnosed multiple myeloma (NDMM). (2018) (2)
- A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM). (2017) (2)
- Understanding the Dose Regimen for Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs): A Quantitative Pharmacologic Perspective (2015) (2)
- Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study (2012) (2)
- CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma (2017) (2)
- The Addition of Bortezomib to Modified R-CHOP as Initial Therapy for Follicular NHL Results in High CR Rate and Is Well Tolerated. (2009) (2)
- The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines. (2009) (2)
- Efficacy and Safety of Triplet Versus Doublet Salvage Therapies Among Patients with Multiple Myeloma (MM) Experiencing Early Relapse: Meta-Analysis of Phase III Randomized Controlled Trials (RCTs) (2015) (2)
- A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma (2012) (2)
- Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice. (2022) (2)
- P07: RESULTS FROM THE CC-220-MM-001 DOSE-EXPANSION PHASE OF IBERDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (2022) (2)
- Deep and Durable Responses with Weekly Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Follow-up of Patients Not Undergoing Stem Cell Transplantation (SCT) (2017) (2)
- Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM). (2020) (2)
- Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses (2018) (2)
- An evaluation of efficiency, safety, tolerability, patient satisfaction, and preference of subcutaneous (SQ) versus intravenous (IV) bortezomib (BTZ) administration in patients with multiple myeloma (MM). (2012) (2)
- Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM). (2013) (2)
- A Molecular Analysis of Cereblon-Related Immunomodulatory Drug Resistance in Commpass Multiple Myeloma Patients (2017) (2)
- Trends in Utilization and Outcomes of Autologous Hematopoietic Cell Transplantation (AHCT) in the Upfront Management of Patients with Multiple Myeloma: A Cibmtr Analysis (2012) (2)
- Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients (2018) (2)
- LYMPHOID NEOPLASIA MLN 4924 , an NAE inhibitor , suppresses AKT and mTOR signaling via upregulation of REDD 1 in human myeloma cells (2014) (2)
- Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL) (2011) (2)
- FGFR3 Associates with and Tyrosine-Phosphorylates p90RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation (2008) (2)
- Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003) (2013) (2)
- Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. (2021) (2)
- Novel treatment approaches for patients with relapsed and refractory multiple myeloma (2006) (2)
- A Phase 1 Study of the Pharmacokinetics (PK) and Safety of Pomalidomide + Low Dose Dexamethasone (POM+LODEX) in Patients (PTS) With Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI) (2015) (2)
- Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy (2017) (2)
- The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma (2022) (2)
- Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study. (2010) (2)
- A Phase I Trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg®) for Advanced MDS and Secondary or Relapsed AML. (2004) (2)
- The AfFIRM Study: A multicenter phase 2 study of single-agent filanesib (ARRY-520) in patients with advanced multiple myeloma (2015) (2)
- A268 Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma (2009) (2)
- A224 Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma (2009) (2)
- Treatment of MM: Upcoming Novel Therapies. (2016) (2)
- Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf) (2020) (2)
- 51TiPKEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM) (2016) (2)
- Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis. (2009) (2)
- OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial (2021) (2)
- Impact of Prior Lenalidomide Treatment on Peripheral Blood Stem Cell (PBSC) Mobilization in Untreated Multiple Myeloma (MM) Patients. (2007) (2)
- Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmrf Commpass Analysis (2019) (2)
- Down to the bitter end. (2014) (2)
- Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple myeloma (RRMM) patients (Pts): Analysis of pooled data. (2011) (2)
- KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) (2021) (2)
- Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM) (2017) (2)
- Central Nervous System Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 172 Patients (2015) (2)
- TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma. (2017) (2)
- Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma (2022) (2)
- Phase 1 clinical trial of KOS-953 + bortezomib (BZ) in relapsed refractory multiple myeloma (MM) (2006) (2)
- When “the same” is really “different” (2006) (2)
- TGR-1202: A Novel, Targeted PI3Kδ Inhibitor in Multiple Myeloma (2012) (2)
- Perifosine Induces DR4/DR5 Expression Leading to Apoptosis That Can Be Enhanced with Exogenous TRAIL, and Blocked with Strategies Directed at DR4/DR5 Inhibition. (2006) (1)
- Patterns of Relapse Among Myeloma Patients Post-Autologous Stem Cell Transplant (2016) (1)
- A349 Phase I/II Trial of Perifosine + Bortezomib in Rel/Ref MM Patients Previously Treated with Bortezomib (2009) (1)
- Heterogeneous Bcl-2 Family Expression In Waldenström Macroglobulinemia Determines Response To Inducers Of Intrinsic Apoptosis (2013) (1)
- Death by a thousand cuts: the slow demise of chemotherapy (2016) (1)
- Extended 5‐Year Follow‐Up of the Phase 3 ELOQUENT‐2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM): MM‐271 (2018) (1)
- Phase II trial for lenalidomide alone in relapsed/refractory aggressive non-Hodgkin lymphoma (2007) (1)
- Changes in Expert Recommendations and Global Practice Patterns from 2012-2015: Results from an Annually Updated Online Decision Aid for Multiple Myeloma (MM) (2015) (1)
- The Multiple Myeloma Research Consortium (MMRC): A Model For Accelerating Development Of Novel Therapies For Multiple Myeloma (2013) (1)
- African American Race As a Risk Factor for Developing Peripheral Neuropathy in Newly Diagnosed Patients with Multiple Myeloma Receiving Bortezomib Induction (2022) (1)
- Comparative analysis of outcomes in African American (AA) and white (W) patients (pts) with multiple myeloma (MM) treated with lenalidomide (LEN) or pomalidomide (POM). (2018) (1)
- P-279: Efficacy, safety, and pharmacokinetics of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma by renal function: a subgroup analysis of the CC-220-MM-001 trial (2022) (1)
- Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study (2020) (1)
- Outcomes for Myeloma in the Era of Lenalidomide Maintenance Are Not Different Among Ethnic Groups Following Autologous Transplant (2014) (1)
- Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma (2018) (1)
- Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study. (2021) (1)
- Molecular Characterization of Bone Marrow and Peripheral Blood Compartments from Patients with Plasma Cell Leukemia in the Mmrf Commpass Study (2019) (1)
- B358 SF1126, A Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequen (2009) (1)
- Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease (2019) (1)
- Evaluating Risk Factors and Outcomes For Clostridium Difficile Infection (CDI) In Stem Cell Transplant (SCT) Recipients (2013) (1)
- T Cell Reconstitution in First 200 Days Post Transplantation Predicts Long Term Survival in Allogeneic Hematopoetic Progenitor Cell Transplantation (HPCT). (2006) (1)
- Up-Front Management of Multiple Myeloma (2010) (1)
- Distribution of Bim Determines MCL-1 Dependence or Co-Dependence on BCL-xL/BCL-2 In Multiple Myeloma (2010) (1)
- Prognostic impact of t(11;14) on PFS1 among patients with myeloma receiving triplet induction therapy. (2022) (1)
- Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial (2022) (1)
- Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. (2017) (1)
- Identification and Molecular Characterization of High-Risk Multiple Myeloma Patients from the MMRF CoMMpass Study at Diagnosis and Progression (2019) (1)
- Hsp 90 B enhances MAST 1-mediated cisplatin resistance by protecting MAST 1 from proteosomal degradation (2019) (1)
- Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Analyses (2018) (1)
- Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis. (2013) (1)
- Update on vantage program to assess combined vorinostat (V) and bortezomib (B) in patients (pts) with relapsed and/or refractory (RR) multiple myeloma (MM). (2010) (1)
- Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone (2018) (1)
- Efficacy and Safety of the Panobinostat-Bortezomib-Dexamethasone Combination in Relapsed or Relapsed/Refractory Multiple Myeloma: Results from the Randomized Panorama 3 Study (2020) (1)
- Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial (2022) (1)
- Therapeutic potential of the Akt inhibitor perifosine in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for metastatic head and neck cancer. (2007) (1)
- Myeloma Patient-Derived MCL1 Point Mutations Can Influence MCL1-Inhibitor Function (2018) (1)
- Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment (2015) (1)
- Inhibition of Heat Shock Factor 1 (HSF1) Is More Effective At Sensitizing Myeloma Cells to Bortezomib Than Inhibition of Individual HSF1 Targets. (2012) (1)
- P865: BIOMARKER ANALYSIS TO SUPPORT DOSE OPTIMIZATION OF IBERDOMIDE AS MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE TREATMENTS FOR MULTIPLE MYELOMA FROM A PHASE 1/2 TRIAL (2022) (1)
- Utility of Clinical-Grade Sequencing of Relapsed Multiple Myeloma Patients; Interim Analysis of the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol (2017) (1)
- Venetoclax ex vivo functional profiling predicts improved progression-free survival (2022) (1)
- Advances in current treatment for patients with newly diagnosed multiple myeloma. (2013) (1)
- Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes (2011) (1)
- Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR) (2018) (1)
- Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial (2011) (1)
- MM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up (2020) (1)
- Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM) (2021) (1)
- Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle (2010) (1)
- PB1983: TRIAL-IN-PROGRESS: PHASE II STUDY OF PHE885, A B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN ADULTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (2022) (1)
- HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS) (2016) (1)
- Updated survival with extended follow-up on patients with newly diagnosed multiple myeloma treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach. (2022) (1)
- Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma (2020) (1)
- Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma (2018) (1)
- Cost-Effectiveness Analysis of a “Just-In-Time” Strategy of Salvage Plerixafor Administration for Poor-Mobilizing Patients Undergoing Autologous Transplant (2010) (1)
- Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplant — Obesity Associated with Inferior Outcomes (2017) (1)
- Impact of obesity on response in 751 myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVd) induction. (2018) (1)
- 50TiPKEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (2016) (1)
- Phase I trial with IPI-504 in relapsed/refractory multiple myeloma (2007) (1)
- Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy (2018) (1)
- Series MULTIPLE MYELOMA : FROM THE BENCH TO BEDSIDE Treatment options for relapsed and refractory multiple myeloma (2015) (1)
- Real World Experience and Patient Satisfaction Surrounding the Implementation of Daratumumab and Hyaluronidase-Fihj in a Large, Academic Medical Center (2020) (1)
- “I took the road less traveled, and that has made all the difference”: Making a case for high‐dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma (2021) (1)
- Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study, (2011) (1)
- Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice (2023) (1)
- Gene integrated set profile analysis: a context-based approach for inferring biological endpoints (2016) (1)
- Normalization of Serum Free Light Chain Ratio After Autologous Stem Cell Transplantation in Multiple Myeloma as a Major Criteria Response (2015) (1)
- Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study (2021) (1)
- Role of clonoSEQ®, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma (2020) (1)
- Bone Marrow Stromal Cells Enforce MCL-1 Dependence In Multiple Myeloma Through the Secretion of A Soluble Factor, (2011) (1)
- Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Commpass Study (2015) (1)
- Real-world outcomes of venetoclax refractory multiple myeloma patients. (2020) (1)
- Explaining the Excess Risk of Multiple Myeloma in African-Americans (2012) (1)
- Characterization of Cytokine Release Syndrome (CRS) in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma (RRMM) (2021) (1)
- Patient reported outcomes (PROs) of multiple myeloma (MM) patients treated with panobinostat (PAN) after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled, PANORAMA-1 trial. (2016) (1)
- Survival trends of myeloma patients in the new millennium. (2014) (1)
- Safety and Efficacy of Evomela™ in Myeloma Autotransplants (2018) (1)
- P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma (2021) (1)
- P-231: Biomarker analysis to support dose optimization of iberdomide (IBER) as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial (2022) (1)
- Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth (2010) (0)
- MM-345: Differential Toxicities and Survival Outcomes by Race: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Myeloma (2020) (0)
- Rare myelomas: sometimes when you hear hooves, it's a zebra... (2013) (0)
- Preliminary results of a phase I/II study of the humanized anti-CD20 antibody IMMU-106 (hA20) in patients with relapsed non-Hodgkin lymphoma (2007) (0)
- Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (2021) (0)
- ABCL-378: Prolonged Cytopenias in Autologous Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2021) (0)
- Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma (2021) (0)
- Management of Back Pain in Myeloma Patients Using Vertebral Augmentation: A Practical Approach to Elimination of Pain and Improvement of Functional Status (2012) (0)
- Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit. (2013) (0)
- The Effect of Rituximab on Mobilization with AMD3100 Plus G-CSF in Patients with Relapsed or Refractory NHL or HD. (2007) (0)
- Preliminary phase I evaluations of 2 anti-CD40 monoclonal antibodies in patients with relapsed/refractory multiple myeloma (2007) (0)
- Abstract 34: Oncogenic tyrosine kinases phosphorylate and inhibit PKM2 to provide a metabolic advantage to tumor growth (2010) (0)
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma (2012) (0)
- High-Risk Myeloma Is Demarcated By Immunoglobulin Lambda Light Chain Translocations (2017) (0)
- P-170: Transplant related morbidities with Melphalan as conditioning regimen for myeloma autotransplants (2021) (0)
- Next Steps in Myeloma Management (2007) (0)
- Results From the Multiple Myeloma Trials (2015) (0)
- Therapeutic Drug Monitoring (TDM) of IV Busulfan in Patients with Severe Obesity. (2007) (0)
- The Role of County-Level Contextual Predictors in Multiple Myeloma Mortality (2015) (0)
- Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans (2019) (0)
- Risk Stratification and Response Assessment in Multiple Myeloma and Waldenström's Macroglobulinemia (2014) (0)
- How Does Genetics and MRD Impact Treatment or Doesn’t It? (2018) (0)
- Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell Analyses (2023) (0)
- Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample (2013) (0)
- Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders (2022) (0)
- Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma (2020) (0)
- EXABS-123-MM Additional Agents for RRMM - How Do/Will They Fit. (2022) (0)
- Insights Into the Appropriate Use of New Antimyeloma Therapies. (2017) (0)
- Idiopathic secondary post-transplant thrombocytopenia (ISPT) following autologous hematopoietic progenitor cell transplantation (HPCT) is associated with transplantation of lower numbers of primitive hematopoietic progenitors (2006) (0)
- Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents (2014) (0)
- A Randomized Clinical Trial Comparing Cytokine Administration Sites for Mobilization of Peripheral Hematopoietic Progenitor Cells for Patients with Hematological Malignancies Undergoing Autologous Stem Cell Transplantation. (2009) (0)
- Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT) (2013) (0)
- Development and Validation of a High Risk Multiple Myeloma Gene Expression Index from RNA Sequencing: An Mmrf Commpass Analysis (2018) (0)
- The Use of An Online Case Database to Obtain Clinical and Psychosocial Information Related to the Selection of and Experience with Initial Systemic Therapy for Multiple Myeloma. (2009) (0)
- Reply to N. Biran et al. (2020) (0)
- Detection of NFKB2 3’end Loos By Quantitative PCR (QPCR) or Detection of NFKB2 Rearrangements Correlate with Bortezomib Response in Multiple Myeloma (2014) (0)
- High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM) (2010) (0)
- Beta adrenergic signaling regulates HSPC commitment and therapy sensitivity in multiple myeloma. (2022) (0)
- P-257: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory multiple myeloma: EXCALIBER-RRMM (2022) (0)
- PB2155 ONLINE CME SIGNIFICANTLY IMPACTS MULTIPLE MYELOMA CLINICIANS: EXPERIENCE FROM A MULTI-YEAR CURRICULUM WITH 33,699 LEARNERS (2019) (0)
- Abstract B58: Decreasing the time to activate clinical trials: Initial data from the Multiple Myeloma Research Consortium (MMRC) model (2009) (0)
- Analysis of Sequential Patient Samples from the Mmrf Commpass Study Identifies a High Risk Progression Phenotype (2018) (0)
- Efficacy of daratumumab + SOC versus SOC in myeloma induction regimens, by risk-stratification: Meta-analysis of phase III randomized control trials. (2020) (0)
- The Graft-Versus-Myeloma Effect Using Non-Myeloablative Or Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (2010) (0)
- ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the NCITrial Complexity and Elements Scoring (NCI-TCES) and the NCI Myeloma Steering Committee Accrual Working Group (NCI MYSC AWG) scoring models. (2014) (0)
- Book Review: Myeloma Therapy: Pursuing the Plasma Cell (2009) (0)
- Dexamethasone Synergizes with ABT-199 through the Induction of Bim and Bcl-2 Dependence in Myeloma (2014) (0)
- The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development (2011) (0)
- Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma (2013) (0)
- Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study) (2022) (0)
- Abstract 4629: Multiple myeloma susceptibility loci examined in African and European ancestry populations (2015) (0)
- Targeting metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to ABT-199 (2015) (0)
- The prognostic significance of donor dendritic cells in allogeneic hematopoietic progenitor cell transplant (2008) (0)
- Reduced-intensity conditioning permits a significant graft vs leukemia (GvL) effect for acute leukemia (2006) (0)
- Multiple Myeloma: State of the Art: 075‐MM‐01 (2017) (0)
- Syddansk Universitet High-Parameter Mass Cytometry Evaluation of Relapsed / Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action (2019) (0)
- The Role of 14-3-3ζ in Regulation of Proteasome Inhibitor Bortezomib Sensitivity in Multiple Myeloma (2012) (0)
- Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease (2008) (0)
- Whole Genome DNA Methylation Analysis of Commpass Identifies Biomarkers of Multiple Myeloma Survival (2018) (0)
- OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (2021) (0)
- Evolving Treatment Patterns of Healthcare Providers (HCPs) and Multiple Myeloma (MM) Experts from 2013-2017: Analysis of an Annually Updated Online Treatment Decision Tool (2017) (0)
- An Integrated Genomics Analysis Identifies Recurrent Gain- and Loss-of-Function Events and in Distinct Subtypes of Multiple Myeloma (2018) (0)
- The Role of Proteasome Activator PA28α in Multiple Myeloma (2019) (0)
- Thrombocytopenia Induced by Combination Administration of Romidepsin and Bortezomib In Mice Is Rapidly Reversible After Drug Treatment (2010) (0)
- Patient Characteristics in CD 20+ and CD 20− Adult Acute Lymphoblastic Leukemia (ALL): A Single Institution Analysis. (2005) (0)
- Clinical ef fi cacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma (2016) (0)
- Abstract 2825: Stromal cell derived IL6 inhibits the extrinsic apoptotic pathway in multiple myeloma cell lines (2022) (0)
- Guideline to Multiple Myeloma Treatment Strategies (2012) (0)
- Myeloma: Treatment of emergent peripheral neuropathy in plasma cell disorders (2013) (0)
- High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler) (2013) (0)
- Aberrant extrafollicular B cells, immune dysfunction, myeloid inflammation and MyD88-mutant progenitors precede malignancy in Waldenstrom macroglobulinemia (2021) (0)
- Real-World Practice Patterns with Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (2014) (0)
- Donor Dendritic Cells Regulate Immune Reconstitution after Allogeneic Bone Marrow Transplantation. (2004) (0)
- Abstract LB-291: Translational studies of the dual mTOR-PI3K inhibitor SF1126 (2010) (0)
- Novel approaches to the treatment of multiple myeloma. (2023) (0)
- Practical approach to the management of smoldering myeloma (2020) (0)
- DNA methylation reprogramming in relapsed/refractory myeloma converges with loci prognostic of survival in newly diagnosed patients (2019) (0)
- P1739: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH IBERDOMIDE PLUS DEXAMETHASONE IN A PHASE 1B/2A OPEN-LABEL DOSE ESCALATION STUDY (2022) (0)
- Practical issues involved with the use of bortezomib (2009) (0)
- Retrotransposons facilitate the tissue-specific horizontal transfer of circulating tumor DNA between human cells (2022) (0)
- 1 Identification of Novel Mutational Drivers Reveals Oncogene Dependencies In Multiple Myeloma . Short title : Oncogene dependencies in myeloma (2018) (0)
- PF559 IBERDOMIDE (CC-220) IS PHARMACODYNAMICALLY ACTIVE AND HAS DOSE-DEPENDENT IMMUNOSTIMULATORY ACTIVITY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IRRESPECTIVE OF PRIOR IMID DRUG TREATMENT (2019) (0)
- Consolidation with High Dose Therapy and Autologous Stem Cell Transplant Improves Survival for Patients with Mantle Cell Lymphoma (2012) (0)
- Oncolytic virus pelareorep plus carfilzomib phase I trial in carfilzomib-refractory patients (NCI 9603): Responses with cytokine storm. (2020) (0)
- Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival. (2012) (0)
- We need CD38 STAT-JAK. (2020) (0)
- 48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL. (2007) (0)
- TRAIL-Induced Apoptosis in Human Lung Cancer Cells Expression of Death Receptor 5 and Enhances The Farnesyltransferase Inhibitor R 115777 Upregulates the (2007) (0)
- Treatment of multiple myeloma: whence truth over belief? (2009) (0)
- Optimizing the benefits of BCMA-targeted CAR T-cell therapy in multiple myeloma. (2023) (0)
- Preview : Published ahead of advance online publication 14-3-3 f binds the proteasome , limits proteolytic function , and enhances sensitivity to proteasome inhibitors (2017) (0)
- Phase III Trial: Bortezomib/Thalidomide/Dexamethasone Versus Thalidomide/Dexamethasone Alone: Efficacy (2009) (0)
- Abstract 2921: Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy (2018) (0)
- Role of PET/CT As a Measure of Minimal Residual Disease (MRD) Negativity Among Patients with Myeloma Post Autologous Stem Cell Transplant (ASCT) (2015) (0)
- Real-World Evaluation of Prolonged and Delayed Cytopenias after Chimeric Antigen Receptor T-Cell Therapy: A Comparison of BCMA and CD19 Based Outcomes (2023) (0)
- Abstract 4913: Differences in presentation and survival outcomes for African American patients with newly diagnosed multiple myeloma (2019) (0)
- Integrative, Multi-Platform, Whole-Genome Analyses Identify Clinically Relevant Common- and Cell-Specific Signatures in Multiple Myeloma (2012) (0)
- Ablation of CD28-86 Signaling Results in Induction of Both Caspase-Dependent and Caspase-Independent Cell Death in Myeloma Cells (2014) (0)
- Predictors of More Rapid Lymphoid Reconstitution after Allogeneic Transplantation. (2004) (0)
- Clinical Characteristics and Outcomes of Myeloma Patients Exhibiting Translocation (14;16): An Ultra-High-Risk Group of Myeloma Patients (2017) (0)
- P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? (2022) (0)
- Frontline regimens for multiple myeloma patients. (2010) (0)
- Relapse Free Survival of Elderly AML Patients Is Comparable to That of Younger Adults When Treated with a Modified Dose Intensive Cytarabine Regimen. (2005) (0)
- Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed dose vinorelbine, paclitaxel, etoposide, and cisplatin (VTEPA) for the treatment of relapsed/refractory lymphoma (2005) (0)
- When an embarrassment of riches isn’t enough (2022) (0)
- β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma (2022) (0)
- Multiple Myeloma : 2007-2008 (2008) (0)
- Faculty Opinions recommendation of A monoclonal gammopathy precedes multiple myeloma in most patients. (2009) (0)
- Multiple myeloma immunoglobulin lambda translocations portend poor prognosis (2019) (0)
- Monoclonal antibodies in multiple myeloma: data from the 2015 ASH meeting. (2016) (0)
- Management of back pain in myeloma patients using kyphoplasty: a practical approach to the reduction of pain, improvement of functional status, and palliative success (2013) (0)
- BI-Modal Age Distribution of Patients with Relapsed Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation Correlates with Markedly Inferior Survival Among Patients Age 35 Years and Older (2012) (0)
- Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma (2020) (0)
- Survival Outcomes of Younger (≤ 50 years) Myeloma Patients (2017) (0)
- BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction (2021) (0)
- Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis (2011) (0)
- patients with newly diagnosed multiple myeloma Lenalidomide, bortezomib, and dexamethasone combination therapy in (2012) (0)
- Lack of Health Maintenance Exams and Risk: An Internet-Based Survey on Health Maintenance and Preventive Care Patterns in Patients with Myeloma (2015) (0)
- Complete remission of multiple myeloma. (2007) (0)
- P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY (2022) (0)
- Oral Selinexor Shows Single Agent Activity Enhanced With PI or IMID Combinations in Refractory Multiple Myeloma (MM) (2017) (0)
- Impact of Revised International Working Group Criteria on Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. (2006) (0)
- NSCLC Cells Up-Regulation of c-FLIP and Survivin Expression in Human Enhancement of TRAIL-Induced Apoptosis Despite DR 5 Expression Leading to Induction of Apoptosis and The Proteasome Inhibitor PS-341 ( Bortezomib ) UpRegulates (2007) (0)
- Areas of Consensus and Differences Among a Panel of Experts on the Optimal Use of Newly Approved Agents to Treat Multiple Myeloma (MM): Results from an Annually Updated Online Decision Support Tool (2016) (0)
- What is the Role for Monoclonal Antibodies in MM? What do the Preclinical Data tell us? (2015) (0)
- CD28 and CD86 Are Necessary for Myeloma Cell Survival. (2012) (0)
- Rituximab does not inhibit chemo-mobilization of HPC or engraftment following autologous transplant for lymphoma (2005) (0)
- Bloodless transplants for multiple myeloma are feasible and yield similar results as matched controls. (2015) (0)
- Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) from the KarMMa Study (2022) (0)
- Conclusion: advances in current treatment for patients with newly diagnosed multiple myeloma. (2013) (0)
- Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study (2008) (0)
- High-risk myeloma: when to transplant-or not. (2014) (0)
- Abstract PR05: A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans (2020) (0)
- Patulin Acts Synergistically with Doxorubicin and Bortezomib in Cytotoxicity against Hematological Malignancies (2008) (0)
- autologous stem cell transplantation treatment of multiple myeloma patients who are candidates for International Myeloma Working Group consensus approach to the (2012) (0)
- Genetic Susceptibility Markers of Multiple Myeloma in African-Americans (2014) (0)
- AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) (2017) (0)
- ElotuzumabinCombinationWithLenalidomideandLow-Dose DexamethasoneinRelapsedorRefractoryMultipleMyeloma (2012) (0)
- Impact of concurrent gabapentin or pregabalin with high‐dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant (2022) (0)
- A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials, (2011) (0)
- P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma (2021) (0)
- Addressing Unmet Medical Needs in Maintenance Treatment for Newly Diagnosed Multiple Myeloma (NDMM): MM‐236 (2018) (0)
- Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study (2015) (0)
- The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study (2018) (0)
- Risk Factors for Development of Myeloma: Role of Smoking and Alcohol (2014) (0)
- Pharmacokinetic (PK) Comparison Of Intravenous Versus Oral Busulfan Conditioning Regimens for Acute Myeloid Leukemia (AML) And Myelodysplastic Syndrome (MDS) Patients (2009) (0)
- Simplified Technique for Administration of High Dose Melphalan (2014) (0)
- US Cooperative Group Trials (2009) (0)
- OAB-012: Early and sustained negative minimal residual disease (MRDneg) after idecabtagene vicleucel (ide-cel) defines a subset of multiple myeloma (MM) patients in KarMMa achieving prolonged survival (2022) (0)
- Abstract 2715: Deciphering a metabolic basis for single-agent venetoclax efficacy in t(11;14) multiple myeloma (2019) (0)
- Tolerability and Anti-Leukemic Activity of Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] in Advanced MDS and AML: Interim Analysis of Phase I/II Data. (2006) (0)
- Disparities in multiple myeloma among African Americans. (2022) (0)
- Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL). (2018) (0)
- MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM) (2021) (0)
- Analysis of outcomes based on response for patients with relapsed or relapsed and refractory multiple myeloma in the phase 3 PANORAMA 1 study. (2015) (0)
- Phase I/II trial of pralatrexate in patients with chemotherapy-resistant precursor and peripheral T-cell lymphomas (2007) (0)
- Preclinical Development The NEDD 8-Activating Enzyme Inhibitor , MLN 4924 , Cooperates with TRAIL to Augment Apoptosis through Facilitating c-FLIP Degradation in Head and Neck Cancer Cells (2011) (0)
- Obesity In Young Adulthood Is Associated With Early Onset Multiple Myeloma In African Americans (2013) (0)
- Putting the E (evidence) in a new Era for myeloma (2011) (0)
- Racial Disparities in Incidence and Survival for Patients with Multiple Myeloma in the United States (2015) (0)
- Correlation Among Different Plasma Cell Disorders Markers and Immunoglobulin Heavy Light Chains (HLC) (2013) (0)
- Abstract 1635: Combination of the HDAC inhibitor romidepsin with the MEK inhibitor U0126 results in synergistic plasma cell apoptosis (2010) (0)
- Causes of mortality in patients with plasma cell disorders. (2014) (0)
- Abstract 319: Syntenin regulates multiple myeloma cell survival (2018) (0)
- Truncation of NF-KB2 Is Associated with Poor Response to Bortezomib Treatment in Multiple Myeloma (2011) (0)
- Characterization of Heat Shock Factor 1 in Response to Proteasome Inhibition Unveils a Novel Therapeutic Strategy for Multiple Myeloma Treatment (2015) (0)
- MULTIPLE MYELOMA: FROM THE BENCH TO BEDSIDE Treatment options for relapsed and refractory multiple myeloma (2015) (0)
- Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial (2021) (0)
- The Farnesyltransferase Inhibitor R 115777 Upregulates the Expression of Death Receptor 5 and Enhances TRAIL-Induced Apoptosis in Human Lung Cancer Cells (2007) (0)
- Melphalan or no melphalan: that is the question. (2010) (0)
- Predicting Venetoclax Sensitivity in Multiple Myeloma Using Biologic Activity Assays (2017) (0)
- P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma (2013) (0)
- A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma (2006) (0)
- Running title: 14-3-3 antagonist R18 induces apoptosis through liberation and reactivation of FOXO3a but not BAD. (2007) (0)
- Safety and Engraftment Parameters for Bloodless Transplants among Myeloma Patients (2017) (0)
- Abstract 223: A meta-analysis of genome-wide association studies of multiple myeloma among African Americans (2018) (0)
- Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies (2014) (0)
- FDA-approved novel agents to treat relapsed and refractory myeloma (2009) (0)
- bortezomib- containing regimens cell collection following initial therapy with thalidomide, lenalidomide or Mobilization in myeloma revisited: IMWG consensus perspectives on stem (2009) (0)
- Registering a CD38 antibody upfront for multiple myeloma (2019) (0)
- Message from the Chairmen. (2020) (0)
- Inhibitors (BCL2 - MCL1 - CDK) (2015) (0)
- Transcriptional and Post-translational Regulation of the Bcl-2 Family by IL-6 Mediates Resistance to ABT-737 in Multiple Myeloma (2013) (0)
- Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High‐risk Population: MM‐257 (2018) (0)
- Extracorporeal Photopheresis Therapy For Chronic Graft-Versus-Host Disease: Response Is Associated With Content Of Dendritic Cells And T-Cells In Peripheral Blood At Initiation Of Treatment (2009) (0)
- AKT inhibitors in multiple myeloma (2013) (0)
- Exposure-Response Relationship of Daratumumab Efficacy and Safety in Patients with Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitors (PIs) and Immunomodulatory Drugs (IMiDs) (2015) (0)
- Clinical response by baseline characteristics in patients with relapsed and bortezomib-refractory multiple myeloma treated with panobinostat, bortezomib, and dexamethasone (PANORAMA 2) (2013) (0)
- Clinical features of patients with multiple myeloma harboring t(4;14) and impact on long-term survival. (2022) (0)
- Combination of Farnesyl Transferase Inhibition (Lonafarnib) and Proteasome Inhibition (Bortezomib) Results in Rapid Caspase Activation and down Regulation of p-AKT in Myeloma cell Lines and Primary Myeloma Cells. (2004) (0)
- CD28 and CD86 Regulate Integrin Surface Expression In Multiple Myeloma (2013) (0)
- Decreased Incidence of Relapse in Patients with Acute Leukemia Transplanted from Matched Unrelated Donors: Induction of GvL. (2005) (0)
- Fusokine GIFT4 triggers novel B Cell function on hematopoietic stem cells (2015) (0)
- Interim analysis of a phase iii randomized, double-blind studyof vorinostat or placebo combined with bortezomib in relapsedmultple myeloma (2010) (0)
- Access to Children’s Oncology Group phase I clinical trials: Racial/ethnic dissimilarities in participation. (2014) (0)
- Abstract 4782: The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through JNK-dependent downregulation of c-FLIP in head and neck cancer cells (2011) (0)
- Infectious outcomes after alternative donor stem cell transplantation: a retrospective cohort comparison (2002) (0)
- Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy (2018) (0)
- Evidence of Improved Knowledge and Skills Among Hematologists/Oncologists Participating in Online CME-Certified Activities (2021) (0)
- Interleukin-6 Enhances the Survival of Myeloma Cells by Regulating Bim Binding to Anti-Apoptotic Bcl-2 Proteins (2012) (0)
- CHALLENGES IN THE MANAGEMENT OF HIGH-RISK MULTIPLE MYELOMA (2023) (0)
- Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT) (2018) (0)
- Hematopoietic cytokines: when treating the symptoms does not treat the disease. (2003) (0)
- Subgroup Analysis by Prior Treatment of the Efficacy and Safety of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma in the PANORAMA 1 Study (2015) (0)
- Access To Therapeutic Surgical Procedures For Pathologic Fractures In Multiple Myeloma Patients: Analysis of Nationwide Inpatient Sample (NIS) (2013) (0)
- Predictors Of Survival Outcomes In Phase I Relapsed Or Refractory Multiple Myeloma Patients (2013) (0)
- Abstract 3852: Obesity is associated with clinical characteristics in African American multiple myeloma patients (2014) (0)
- Practical considerations for multiple myeloma: an overview of recent data and current options. (2008) (0)
- Commentary (Kaufman/Lonial): New Treatments for Multiple Myeloma (2005) (0)
- Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM) (2018) (0)
- Clinical response by baseline characteristics in patients (pts) with relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2). (2013) (0)
- A Role for Syntenin-1 in Multiple Myeloma Cell Survival (2018) (0)
- In-Depth Molecular Profiling of Multiple Myeloma in African Americans (2015) (0)
- Multiple myeloma gammopathies A high-risk , Double-Hit , group of newly diagnosed myeloma identi fi ed by genomic analysis (2018) (0)
- ATLAS: Risk-adapted Triplet Maintenance with Carfilzomib, Lenalidomide and Dexamethasone – Still Shrugging? (2022) (0)
- Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study (2019) (0)
- A Randomized Trial to Evaluate the Impact of Cytokines on Dendritic Cell, T-Cell and T-Cell Function When Mobilizing Normal Donors for Allogeneic Progenitor Cell Transplant: An Interim Analysis. (2004) (0)
- Does the magnitude of response to initial induction therapy impact plans for immediate autologous stem cell transplant (ASCT) consolidation in the transplant-eligible patient with a new diagnosis of multiple myeloma (MM)? (2010) (0)
- Validation of the Function of 14-3-3 ζ in Multiple Myeloma (MM) (2011) (0)
- Serum Heavy Light Chain Ratio Normalization Among Multiple Myeloma Patients Achieving sCR (2015) (0)
- A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma (2023) (0)
- Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience (2023) (0)
- IMiD-based Triplet Therapy for Multiple Myeloma (2015) (0)
- p90RSK2 as a Therapeutic Target in Treatment of FGFR3-Expressing t(4;14) Multiple Myeloma. (2007) (0)
- Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy (2018) (0)
- Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Efficacy Analysis of PrE1003, a Precog Study (2016) (0)
- University of Southern Denmark High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action (2019) (0)
- University of Southern Denmark Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed / Refractory Multiple Myeloma (2017) (0)
- Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era (2020) (0)
- B356 Imipramine Blue, a Tricyclic Compound and an Inhibitor of NADPH Oxidase Induces G2/M Cell-Cycle Arrest (2009) (0)
- Imipramine Blue, a Tricyclic Compound and An Inhibitor of NADPH Oxidase Induces G2/M Cell Cycle Arrest Followed by Apoptosis in Multiple Myeloma Cells and in Leukemia Cells (2008) (0)
- Combined Carfilzomib and Selective PI3Kδ Inhibition (TGR1202) Results In Enhanced Myeloma Cell Apoptosis (2013) (0)
- Patients Receiving Palifermin in Conjunction with Melphalan 200 Required Fewer Platelet Transfusions: Analysis of a Retrospective Cohort Study. (2006) (0)
- Prioritizing Content in Continuing Hematologic Oncology Education: A Survey of 51 Clinical Investigators (2012) (0)
- Abstract 4561: The MMRF CoMMpassSM Study: A prospective, longitudinal, multicenter observational study in newly diagnosed multiple myeloma patients to assess the relationship between patient outcomes, treatment regimens and molecular profiles (2012) (0)
- Infliximab for the Treatment of Chronic Graft Versus Host Disease. (2006) (0)
- What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma. (2021) (0)
- The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma (2011) (0)
- Improving Patient Care Through Clinical Process Optimization (2017) (0)
- DC 2 Effect on Survival Following Allogeneic Bone Marrow Transplantation (2017) (0)
- Investigation of Mechanisms of Response in Multiple Myeloma Via Bayesian Causal Inference: An Early Analysis of the Commpass Study Data (2015) (0)
- Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies (2019) (0)
- Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma (2021) (0)
- 1458 Regulation of neoantigen specific T cell infiltration and spatial tumor immune architecture of myeloma and its premalignant precursors (2022) (0)
- Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies (2021) (0)
- Older Patients with Hodgkin Lymphoma (HL) Undergoing Autologous Stem Cell Transplantation for Relapsed/Refractory Disease Have Inferior Survival Compared to Younger Patients (2011) (0)
- A227 Lenalidomide, Bortezomib, and Dexamethasone Is Active in High-Risk Relapsed/Refractory Myeloma (2009) (0)
- Correction: Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IκBα degradation (2020) (0)
- (1165) Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation. Session Type: Poster Session, Board #319-I (2007) (0)
- Clinical Impact of an Internet-Based Tool to Provide Expert Guidance for Multiple Myeloma (MM) from 2012 to 2014 (2014) (0)
- Autologous hematopoietic transplant in multiple myeloma (2017) (0)
- Optimization of chemo-mobilization of autologous blood hematopoietic progenitor cell grafts (2004) (0)
- Future directions in immunomodulatory therapy (2010) (0)
- A Phase 2 Evaluation of Daratumumab-Based Induction Therapy in Multiple Myeloma Patients with Severe Renal Insufficiency (2022) (0)
- Preclinical rationale leading to clinical benefit: Multiple myeloma as a poster child (2008) (0)
- B350 SNS-032, a Potent and Selective CDK2, 7 and 9 Inhibitor, Demonstrates Preclinical Activity in Human Multiple Myeloma (2009) (0)
- The White House crusade against ... MGUS? (2010) (0)
- Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study (2018) (0)
- A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin’s Lymphoma (2014) (0)
- 14-3-3 Integrates Pro-Survival Signals in Hematopoietic Cells Transformed by Diverse Leukemogenic Tyrosine Kinases, and Represents a Common Target. (2006) (0)
- ETV1 Is a Survival Gene That Is Expressed in a Subset of Multiple Myeloma (2011) (0)
- assessment Eliminating the complete response penalty from myeloma response (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sagar Lonial?
Sagar Lonial is affiliated with the following schools:
